Additional Use of Trimetazidine in Patients With Chronic Heart Failure

Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital of Fudan University, Shanghai, China.
Journal of the American College of Cardiology (Impact Factor: 15.34). 03/2012; 59(10):913-22. DOI: 10.1016/j.jacc.2011.11.027
Source: PubMed

ABSTRACT The aim of this meta-analysis was to evaluate the effects of additional trimetazidine (TMZ) treatment on patients with chronic heart failure (CHF).
Conflicting results currently exist on the clinical use of TMZ in CHF patients.
PubMed, MEDLINE, EMBASE, and EBM Reviews databases were searched through November 2010 for randomized controlled trials (RCTs) assessing TMZ treatment in CHF patients. Data concerning the study design, patient characteristics, and outcomes were extracted. Risk ratio (RR) and weighted mean differences (WMD) were calculated using fixed or random effects models.
Sixteen RCTs involving 884 CHF patients were included. Hospitalization for cardiac causes (RR: 0.43, p = 0.03), but not all-cause mortality (RR: 0.47, p = 0.27), was reduced by TMZ treatment. Moreover, TMZ therapy was associated not only with the increase of left ventricular ejection fraction (WMD: 6.46%, p < 0.0001) and total exercise time (WMD: 63.75 seconds, p < 0.0001), but also with the decrease of New York Heart Association functional class (WMD: -0.57, p = 0.0003), left ventricular end-systolic diameter (WMD: -6.67 mm, p < 0.0001), left ventricular end-diastolic diameter (WMD: -6.05 mm, p < 0.0001), and B-type natriuretic peptide (WMD: -203.40 pg/ml, p = 0.0002).
Additional use of TMZ in CHF patients may decrease hospitalization for cardiac causes, improve clinical symptoms and cardiac function, and simultaneously ameliorate left ventricular remodeling.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Metabolic and cardiovascular disease patients have increased plasma levels of lipids and, specifically, of palmitate, which can be toxic for several tissues. Trimetazidine (TMZ), a partial inhibitor of lipid oxidation, has been proposed as metabolic modulator for several cardiovascular pathologies. However, its mechanism of action is controversial. Given the fact that TMZ is able to alter mitochondrial metabolism, we evaluated the protective role of TMZ on mitochondrial morphology and function in an in vitro model of lipotoxicity induced by palmitate. We treated cultured rat cardiomyocytes with BSA-conjugated palmitate (25nM free), TMZ (0.1-100μM), or a combination of both. We evaluated mitochondrial morphology and lipid accumulation by confocal fluorescence microscopy, parameters of mitochondrial metabolism (mitochondrial membrane potential, oxygen consumption rate [OCR], and ATP levels), and ceramide production by mass spectrometry and indirect immunofluorescence. Palmitate promoted mitochondrial fission evidenced by a decrease in mitochondrial volume (50%) and an increase in the number of mitochondria per cell (80%), whereas TMZ increased mitochondrial volume (39%), and decreased mitochondrial number (56%), suggesting mitochondrial fusion. Palmitate also decreased mitochondrial metabolism (ATP levels and OCR), while TMZ potentiated all the metabolic parameters assessed. Moreover, pretreatment with TMZ protected the cardiomyocytes from palmitate-induced mitochondrial fission and dysfunction. TMZ also increased lipid accumulation in cardiomyocytes, and prevented palmitate-induced ceramide production. Our data show that TMZ protects cardiomyocytes by changing intracellular lipid management. Thus, the beneficial effects of TMZ on patients with different cardiovascular pathologies can be related to modulation of the mitochondrial morphology and function.
    Biochemical Pharmacology 10/2014; 91(3):323. DOI:10.1016/j.bcp.2014.07.022 · 4.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiac energetic impairment is a frequent finding in patients with both inherited and acquired diseases of heart muscle. In this review the mechanisms of energy generation in the healthy heart and their disturbances in heart muscle diseases are described. Therapeutic agents targeted at correcting cardiac energetic impairment are discussed. © 2014 American Heart Association, Inc.
    Circulation Cardiovascular Genetics 10/2014; 7(5):720-728. DOI:10.1161/CIRCGENETICS.114.000221 · 6.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The prevalence of patients with concomitant diabetes mellitus and heart failure is growing exponentially. Patients with heart failure and diabetes mellitus show specific metabolic, neurohormonal and structural heart abnormalities, which potentially contribute to worse heart failure outcomes compared to those patients without comorbid diabetes mellitus. Sub-group analysis of recent trials suggest that patients with heart failure and diabetes mellitus may respond differently to standard therapy, and data are emerging on the possible increase in the risk of hospitalizations for heart failure in patients with diabetes mellitus treated with specific class of anti-diabetic agents, pointing to the need of developing specific medications to be tested in dedicated future studies in order to address the unique metabolic and hemodynamic alterations seen in these patients.
    Current Problems in Cardiology 09/2014; 40(1). DOI:10.1016/j.cpcardiol.2014.09.002 · 2.17 Impact Factor


Available from